Matches in SemOpenAlex for { <https://semopenalex.org/work/W1806990171> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W1806990171 endingPage "318" @default.
- W1806990171 startingPage "314" @default.
- W1806990171 abstract "Abstract Background/purpose In biliary tract cancer, few clinical studies evaluating immunotherapy have been reported. A phase I and randomized phase II study with Wilms tumor 1 (WT1) peptide vaccine plus gemcitabine and cisplatin (GC) for chemo‐naïve patients with unresectable or recurrent biliary tract cancer was started, because the overexpression of WT1 is seen in the majority of patients with this disease, encouraging the potential of WT1‐based immunotherapy. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000004886. Methods and results The aim of this trial is to evaluate the efficacy and safety of the regimen and to determine whether the regimen should be compared with the current standard regimen, GC, in a subsequent phase III trial for patients with unresectable or recurrent biliary tract cancer. Six patients in the phase I study and a total of 100 patients in the phase II study will be accrued over a 2‐year period. The patients in the phase II study will be randomized at a 2:1 ratio to receive GC either with or without WT1 peptide vaccine. The primary endpoint of the phase II study is the 1‐year overall survival rate. Conclusions This is the first randomized trial to evaluate the use of immunotherapy in patients with advanced biliary tract cancer." @default.
- W1806990171 created "2016-06-24" @default.
- W1806990171 creator A5012306452 @default.
- W1806990171 creator A5050530209 @default.
- W1806990171 creator A5056206082 @default.
- W1806990171 creator A5076696174 @default.
- W1806990171 date "2012-01-25" @default.
- W1806990171 modified "2023-09-25" @default.
- W1806990171 title "Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplat" @default.
- W1806990171 cites W2013711321 @default.
- W1806990171 cites W2037970435 @default.
- W1806990171 cites W2046064533 @default.
- W1806990171 cites W2062024852 @default.
- W1806990171 cites W2087336559 @default.
- W1806990171 cites W2097995306 @default.
- W1806990171 cites W2109302659 @default.
- W1806990171 cites W2115261608 @default.
- W1806990171 cites W2134121541 @default.
- W1806990171 cites W2149752186 @default.
- W1806990171 doi "https://doi.org/10.1007/s00534-011-0495-1" @default.
- W1806990171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22273718" @default.
- W1806990171 hasPublicationYear "2012" @default.
- W1806990171 type Work @default.
- W1806990171 sameAs 1806990171 @default.
- W1806990171 citedByCount "11" @default.
- W1806990171 countsByYear W18069901712013 @default.
- W1806990171 countsByYear W18069901712014 @default.
- W1806990171 countsByYear W18069901712016 @default.
- W1806990171 countsByYear W18069901712017 @default.
- W1806990171 countsByYear W18069901712018 @default.
- W1806990171 countsByYear W18069901712019 @default.
- W1806990171 countsByYear W18069901712021 @default.
- W1806990171 countsByYear W18069901712022 @default.
- W1806990171 countsByYear W18069901712023 @default.
- W1806990171 crossrefType "journal-article" @default.
- W1806990171 hasAuthorship W1806990171A5012306452 @default.
- W1806990171 hasAuthorship W1806990171A5050530209 @default.
- W1806990171 hasAuthorship W1806990171A5056206082 @default.
- W1806990171 hasAuthorship W1806990171A5076696174 @default.
- W1806990171 hasBestOaLocation W18069901711 @default.
- W1806990171 hasConcept C121608353 @default.
- W1806990171 hasConcept C126322002 @default.
- W1806990171 hasConcept C143998085 @default.
- W1806990171 hasConcept C168563851 @default.
- W1806990171 hasConcept C203092338 @default.
- W1806990171 hasConcept C2777701055 @default.
- W1806990171 hasConcept C2780258809 @default.
- W1806990171 hasConcept C2781413609 @default.
- W1806990171 hasConcept C31760486 @default.
- W1806990171 hasConcept C535046627 @default.
- W1806990171 hasConcept C71924100 @default.
- W1806990171 hasConcept C90924648 @default.
- W1806990171 hasConceptScore W1806990171C121608353 @default.
- W1806990171 hasConceptScore W1806990171C126322002 @default.
- W1806990171 hasConceptScore W1806990171C143998085 @default.
- W1806990171 hasConceptScore W1806990171C168563851 @default.
- W1806990171 hasConceptScore W1806990171C203092338 @default.
- W1806990171 hasConceptScore W1806990171C2777701055 @default.
- W1806990171 hasConceptScore W1806990171C2780258809 @default.
- W1806990171 hasConceptScore W1806990171C2781413609 @default.
- W1806990171 hasConceptScore W1806990171C31760486 @default.
- W1806990171 hasConceptScore W1806990171C535046627 @default.
- W1806990171 hasConceptScore W1806990171C71924100 @default.
- W1806990171 hasConceptScore W1806990171C90924648 @default.
- W1806990171 hasIssue "4" @default.
- W1806990171 hasLocation W18069901711 @default.
- W1806990171 hasLocation W18069901712 @default.
- W1806990171 hasOpenAccess W1806990171 @default.
- W1806990171 hasPrimaryLocation W18069901711 @default.
- W1806990171 hasRelatedWork W2008828217 @default.
- W1806990171 hasRelatedWork W2049717399 @default.
- W1806990171 hasRelatedWork W2088563918 @default.
- W1806990171 hasRelatedWork W2147938475 @default.
- W1806990171 hasRelatedWork W2327780098 @default.
- W1806990171 hasRelatedWork W2464098867 @default.
- W1806990171 hasRelatedWork W3088178260 @default.
- W1806990171 hasRelatedWork W4244958335 @default.
- W1806990171 hasRelatedWork W4245350508 @default.
- W1806990171 hasRelatedWork W2125019270 @default.
- W1806990171 hasVolume "19" @default.
- W1806990171 isParatext "false" @default.
- W1806990171 isRetracted "false" @default.
- W1806990171 magId "1806990171" @default.
- W1806990171 workType "article" @default.